Cargando…
Premature Adrenarche in Children with Prader-Willi Syndrome Treated with Recombinant Human Growth Hormone Seems to Not Influence the Course of Central Puberty and the Efficacy and Safety of the Therapy
Puberty in children with Prader-Willi syndrome (PWS) is usually delayed and/or incomplete but in some patients premature/early adrenarche is observed. We assessed the premature adrenarche (PA) in PWS patients during the recombinant human growth hormone (rhGH) therapy and influence of PA on the cours...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600779/ https://www.ncbi.nlm.nih.gov/pubmed/33050529 http://dx.doi.org/10.3390/life10100237 |
_version_ | 1783603234504441856 |
---|---|
author | Lecka-Ambroziak, Agnieszka Wysocka-Mincewicz, Marta Marszałek-Dziuba, Kamila Rudzka-Kocjan, Agnieszka Szalecki, Mieczysław |
author_facet | Lecka-Ambroziak, Agnieszka Wysocka-Mincewicz, Marta Marszałek-Dziuba, Kamila Rudzka-Kocjan, Agnieszka Szalecki, Mieczysław |
author_sort | Lecka-Ambroziak, Agnieszka |
collection | PubMed |
description | Puberty in children with Prader-Willi syndrome (PWS) is usually delayed and/or incomplete but in some patients premature/early adrenarche is observed. We assessed the premature adrenarche (PA) in PWS patients during the recombinant human growth hormone (rhGH) therapy and influence of PA on the course of central puberty (CP), rhGH efficacy and safety, and patients’ metabolic state. Forty-nine PWS patients were treated with rhGH, 11 presented with PA (group 1) and 14 had normal course of adrenarche (group 2). PA was observed in 22.5% of the PWS children treated with rhGH. The mean time between the rhGH start and the adrenarche, the rhGH dose, the growth velocity and the insulin-like growth factor 1 SD (IGF1 SD) during the treatment, as well as the time of CP, final height SD and BMI SD were similar in both groups. There were also no significant differences in the metabolic assessment—the oral glucose tolerance test (OGTT) and lipid profile results. PA may be a part of the clinical picture of PWS, apart from hypogonadotrophic hypogonadism and it seems to have no influence on CP in PWS patients. The rhGH efficacy and safety were comparable in the patients with PA and the normal course of adrenarche. |
format | Online Article Text |
id | pubmed-7600779 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76007792020-11-01 Premature Adrenarche in Children with Prader-Willi Syndrome Treated with Recombinant Human Growth Hormone Seems to Not Influence the Course of Central Puberty and the Efficacy and Safety of the Therapy Lecka-Ambroziak, Agnieszka Wysocka-Mincewicz, Marta Marszałek-Dziuba, Kamila Rudzka-Kocjan, Agnieszka Szalecki, Mieczysław Life (Basel) Article Puberty in children with Prader-Willi syndrome (PWS) is usually delayed and/or incomplete but in some patients premature/early adrenarche is observed. We assessed the premature adrenarche (PA) in PWS patients during the recombinant human growth hormone (rhGH) therapy and influence of PA on the course of central puberty (CP), rhGH efficacy and safety, and patients’ metabolic state. Forty-nine PWS patients were treated with rhGH, 11 presented with PA (group 1) and 14 had normal course of adrenarche (group 2). PA was observed in 22.5% of the PWS children treated with rhGH. The mean time between the rhGH start and the adrenarche, the rhGH dose, the growth velocity and the insulin-like growth factor 1 SD (IGF1 SD) during the treatment, as well as the time of CP, final height SD and BMI SD were similar in both groups. There were also no significant differences in the metabolic assessment—the oral glucose tolerance test (OGTT) and lipid profile results. PA may be a part of the clinical picture of PWS, apart from hypogonadotrophic hypogonadism and it seems to have no influence on CP in PWS patients. The rhGH efficacy and safety were comparable in the patients with PA and the normal course of adrenarche. MDPI 2020-10-10 /pmc/articles/PMC7600779/ /pubmed/33050529 http://dx.doi.org/10.3390/life10100237 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lecka-Ambroziak, Agnieszka Wysocka-Mincewicz, Marta Marszałek-Dziuba, Kamila Rudzka-Kocjan, Agnieszka Szalecki, Mieczysław Premature Adrenarche in Children with Prader-Willi Syndrome Treated with Recombinant Human Growth Hormone Seems to Not Influence the Course of Central Puberty and the Efficacy and Safety of the Therapy |
title | Premature Adrenarche in Children with Prader-Willi Syndrome Treated with Recombinant Human Growth Hormone Seems to Not Influence the Course of Central Puberty and the Efficacy and Safety of the Therapy |
title_full | Premature Adrenarche in Children with Prader-Willi Syndrome Treated with Recombinant Human Growth Hormone Seems to Not Influence the Course of Central Puberty and the Efficacy and Safety of the Therapy |
title_fullStr | Premature Adrenarche in Children with Prader-Willi Syndrome Treated with Recombinant Human Growth Hormone Seems to Not Influence the Course of Central Puberty and the Efficacy and Safety of the Therapy |
title_full_unstemmed | Premature Adrenarche in Children with Prader-Willi Syndrome Treated with Recombinant Human Growth Hormone Seems to Not Influence the Course of Central Puberty and the Efficacy and Safety of the Therapy |
title_short | Premature Adrenarche in Children with Prader-Willi Syndrome Treated with Recombinant Human Growth Hormone Seems to Not Influence the Course of Central Puberty and the Efficacy and Safety of the Therapy |
title_sort | premature adrenarche in children with prader-willi syndrome treated with recombinant human growth hormone seems to not influence the course of central puberty and the efficacy and safety of the therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7600779/ https://www.ncbi.nlm.nih.gov/pubmed/33050529 http://dx.doi.org/10.3390/life10100237 |
work_keys_str_mv | AT leckaambroziakagnieszka prematureadrenarcheinchildrenwithpraderwillisyndrometreatedwithrecombinanthumangrowthhormoneseemstonotinfluencethecourseofcentralpubertyandtheefficacyandsafetyofthetherapy AT wysockamincewiczmarta prematureadrenarcheinchildrenwithpraderwillisyndrometreatedwithrecombinanthumangrowthhormoneseemstonotinfluencethecourseofcentralpubertyandtheefficacyandsafetyofthetherapy AT marszałekdziubakamila prematureadrenarcheinchildrenwithpraderwillisyndrometreatedwithrecombinanthumangrowthhormoneseemstonotinfluencethecourseofcentralpubertyandtheefficacyandsafetyofthetherapy AT rudzkakocjanagnieszka prematureadrenarcheinchildrenwithpraderwillisyndrometreatedwithrecombinanthumangrowthhormoneseemstonotinfluencethecourseofcentralpubertyandtheefficacyandsafetyofthetherapy AT szaleckimieczysław prematureadrenarcheinchildrenwithpraderwillisyndrometreatedwithrecombinanthumangrowthhormoneseemstonotinfluencethecourseofcentralpubertyandtheefficacyandsafetyofthetherapy |